nodes	percent_of_prediction	percent_of_DWPC	metapath
Nevirapine—CYP3A5—Cyclosporine—focal segmental glomerulosclerosis	0.332	0.374	CbGbCtD
Nevirapine—CYP2C9—Cyclosporine—focal segmental glomerulosclerosis	0.222	0.251	CbGbCtD
Nevirapine—CYP2D6—Cyclosporine—focal segmental glomerulosclerosis	0.203	0.229	CbGbCtD
Nevirapine—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.129	0.146	CbGbCtD
Nevirapine—Traumatic liver injury—Cyclosporine—focal segmental glomerulosclerosis	0.00968	0.0856	CcSEcCtD
Nevirapine—Bullous eruption—Cyclosporine—focal segmental glomerulosclerosis	0.00913	0.0807	CcSEcCtD
Nevirapine—Hypertriglyceridaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00628	0.0556	CcSEcCtD
Nevirapine—Blood triglycerides increased—Cyclosporine—focal segmental glomerulosclerosis	0.00551	0.0487	CcSEcCtD
Nevirapine—Hepatotoxicity—Cyclosporine—focal segmental glomerulosclerosis	0.00467	0.0413	CcSEcCtD
Nevirapine—Liver injury—Cyclosporine—focal segmental glomerulosclerosis	0.00429	0.0379	CcSEcCtD
Nevirapine—Rhabdomyolysis—Cyclosporine—focal segmental glomerulosclerosis	0.00408	0.0361	CcSEcCtD
Nevirapine—Hepatocellular injury—Cyclosporine—focal segmental glomerulosclerosis	0.00361	0.0319	CcSEcCtD
Nevirapine—Lymphadenopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00307	0.0271	CcSEcCtD
Nevirapine—Hepatic failure—Cyclosporine—focal segmental glomerulosclerosis	0.00291	0.0258	CcSEcCtD
Nevirapine—Dermatitis bullous—Cyclosporine—focal segmental glomerulosclerosis	0.00274	0.0242	CcSEcCtD
Nevirapine—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00222	0.0196	CcSEcCtD
Nevirapine—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00204	0.0181	CcSEcCtD
Nevirapine—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.00198	0.0175	CcSEcCtD
Nevirapine—Neuropathy peripheral—Cyclosporine—focal segmental glomerulosclerosis	0.00198	0.0175	CcSEcCtD
Nevirapine—Jaundice—Cyclosporine—focal segmental glomerulosclerosis	0.00197	0.0174	CcSEcCtD
Nevirapine—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.00196	0.0173	CcSEcCtD
Nevirapine—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.00191	0.0169	CcSEcCtD
Nevirapine—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00181	0.016	CcSEcCtD
Nevirapine—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00178	0.0157	CcSEcCtD
Nevirapine—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00146	0.0129	CcSEcCtD
Nevirapine—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00146	0.0129	CcSEcCtD
Nevirapine—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.00144	0.0127	CcSEcCtD
Nevirapine—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.00142	0.0126	CcSEcCtD
Nevirapine—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.00134	0.0119	CcSEcCtD
Nevirapine—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.00134	0.0119	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.00133	0.0118	CcSEcCtD
Nevirapine—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00133	0.0117	CcSEcCtD
Nevirapine—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.00129	0.0114	CcSEcCtD
Nevirapine—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.00129	0.0114	CcSEcCtD
Nevirapine—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00126	0.0112	CcSEcCtD
Nevirapine—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00126	0.0111	CcSEcCtD
Nevirapine—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00125	0.0111	CcSEcCtD
Nevirapine—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.00123	0.0109	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00117	0.0104	CcSEcCtD
Nevirapine—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00116	0.0102	CcSEcCtD
Nevirapine—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.00114	0.0101	CcSEcCtD
Nevirapine—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00112	0.0099	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00111	0.00983	CcSEcCtD
Nevirapine—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.00111	0.00981	CcSEcCtD
Nevirapine—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.0011	0.00973	CcSEcCtD
Nevirapine—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.00106	0.00938	CcSEcCtD
Nevirapine—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00105	0.00931	CcSEcCtD
Nevirapine—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.00102	0.00904	CcSEcCtD
Nevirapine—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00102	0.009	CcSEcCtD
Nevirapine—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.00102	0.009	CcSEcCtD
Nevirapine—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.000948	0.00839	CcSEcCtD
Nevirapine—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000923	0.00817	CcSEcCtD
Nevirapine—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.000911	0.00805	CcSEcCtD
Nevirapine—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000881	0.00779	CcSEcCtD
Nevirapine—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000818	0.00724	CcSEcCtD
Nevirapine—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000811	0.00718	CcSEcCtD
Nevirapine—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000811	0.00717	CcSEcCtD
Nevirapine—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000806	0.00713	CcSEcCtD
Nevirapine—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.000764	0.00676	CcSEcCtD
